What about early-stage dialogues on these assessments?
HTA should be based on an in-depth interaction to discuss specific data required in order to decide on the reimbursement of a product, and looking at its specific field and patient need. This would create predictability by clarifying payer expectations and the ability of industry to meet these expectations. At present, dialogue generally starts when a therapy has been approved. What constitutes therapeutic progress, and whether and at what level to fund this progress should be much clearer, and the rarity of the disease should be taken into account.